Please login to the form below

Not currently logged in
Email:
Password:

Advanced Accelerator Applications

This page shows the latest Advanced Accelerator Applications news and features for those working in and with pharma, biotech and healthcare.

Novartis buys cancer specialist Endocyte for $2.1bn

Novartis buys cancer specialist Endocyte for $2.1bn

177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, acquired along with French company Advanced Accelerator Applications for $3.9bn a year ago.

Latest news

  • Novartis follows Pfizer and freezes US prices this year Novartis follows Pfizer and freezes US prices this year

    ploughing the cash back into the pipeline-enriching acquisitions of gene therapy company AveXis and radiopharma specialist Advanced Accelerator Applications – and going ahead with the spin-off its Alcon eyecare unit.

  • AAA board presses go on $3.9bn Novartis takeover AAA board presses go on $3.9bn Novartis takeover

    French radiopharmaceuticals firm backs the cash offer. Novartis has started its cash tender offer for French firm Advanced Accelerator Applications, which specialises in radiopharmaceuticals to treat cancer.

  • Novartis to buy French radiopharma specialist AAA for $3.9bn Novartis to buy French radiopharma specialist AAA for $3.9bn

    Novartis has agreed a $3.9bn deal to buy Advanced Accelerator Applications, a French company specialising in nuclear medicines used to treat tumours. ... The transaction gives Novartis “both near-term product launches as well as a new technology

  • AAA’s orphan drug Lutathera wins EU green light AAA’s orphan drug Lutathera wins EU green light

    The first-in-class drug treats adults with GEP-NET. Advanced Accelerator Applications’ (AAA) Lutathera (lutetium oxodotreotide) has received European approval to treat adults with unresectable or metastatic, somatostatin receptor positive

  • CHMP backs three immuno-oncology drugs for solid tumours CHMP backs three immuno-oncology drugs for solid tumours

    Advanced Accelerator Applications secured a recommendation for Lutathera (lutetium [177Lu] oxodotreotide) - for the treatment of gastro-entero-pancreatic neuroendocrine tumours - and Ipsen got the nod for Xermelo (telotristat ethyl) as a

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • 3 Monkeys Zeno

    If you’d like to know more healthcare@3monkeyszeno.com Or visit; Merck, Bayer, Boehringher Ingelheim, Novartis, Hologic, Netflix, SilverCloud, Advanced Accelerator Applications,  Perrigo.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics